Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-??. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.
Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-??. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
